Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Telemedicine, Hospitals May Have More Flexible Access To 340B Drug Discounts

Executive Summary

But should a patient with little connection to a 340B covered entity other than through a telehealth visit be considered eligible for a discounted drug under the program?

You may also be interested in...



PhRMA Starts New Year With Familiar Drug Pricing Proposals Targeting The Supply Chain

Hoping to revive interest in rebate reform, PhRMA releases study saying manufacturers retain a shrinking portion of gross branded drug revenues as products move through the supply chain. The pricing distortion underscores the importance of targeting practices by payers and hospitals, the trade group argues.

340B Freeze: 'Mega-Guidance' Withdrawn; Clarity On Program Boundaries Delayed Again

Long-delayed effort to define key boundaries for 340B drug discount program is on hold once again – and it may now take legislation to enable HRSA to move forward with plans to better define who is eligible for the discount.

Medicare Part D Coverage For Obesity Drugs Urged By House Appropriations Panel

In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS142164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel